Our Approach to Innovation
 

We Believe that Innovation is the Key to Simplifying Life for People with Diabetes

People with diabetes make an average of 300 decisions each day1 in managing their condition. Our Goal is to reduce the burden of diabetes care and simplify the user experience. Our Mission is to create insulin delivery that adapts to changing diabetes needs.

Pod shown without the necessary adhesive.

Innovation in Every Pod

One small, tubeless and waterproof2 Pod, which is made up of 74 pieces, consistently and accurately delivers insulin for people with diabetes through customizable basal rates and bolus presets.

The Pod holds up to 200 units of rapid-acting U-100 insulin and replaces up to 14 daily injections.3

The Pod includes auto-cannula insertion, that eliminates the necessity of handling the insertion needle, while providing a virtually pain-free path for insulin delivery.

Insulet Product Roadmap

We are dedicated to reducing complexity and making diabetes management simpler. Our ongoing commitment to the diabetes community is our continuous innovation, aiming to continually make products smarter and simpler. 

The Omnipod® 5 System is the first and only  FDA-cleared tubeless Automated Insulin Delivery System! 

Pod and Dexcom G6 shown without necessary adhesive.

Register for Omnipod® Connect!

Omnipod® Connect is designed to help HCPs learn more about Omnipod® products, including the Omnipod® 5 System. We have developed several e-learning modules in bite-sized lessons, so you can learn about the System and familiarize yourself with best practices for initiation ahead of product availability. You can also connect virtually with an Omnipod® 5 clinical trial investigator through a dedicated 30-minute webinar with live Q&A.

 
 

“The Pod is a revolution in insulin therapy - No tubes, less needle sticks, constant insulin delivery for 3 days - no disconnect. All of these factors improve adherence among people with diabetes and, as a result, dramatically improve clinical outcomes and quality of life.”

Dr. Michael R. Brennan

D.O., M.S., F.A.C.E., F.A.C.P., is an award-winning endocrinology, diabetes and metabolism specialist and founder of the Beaumont Endocrine Center

Get the Latest Updates

Healthcare Providers: Be the first to hear about updates from the Omnipod® Team.

Hear from Industry Experts and Innovation Leaders

“Our research and development team continues to push the boundaries of what’s possible. Through device miniaturization, therapy automation through artificial intelligence, and integration with consumer technologies, we create simple products that deliver great outcomes and reduce the burden for people with diabetes - and those who care for them.”

—Eric Benjamin SVP, Innovation and Strategy, Insulet Corporation

 
Awards & Recognition

Our greatest reward is the impact our products have on the people who use them and their caregivers. We’re also pleased that our hard work and advanced approach have been recognized by industry organizations.

2021

  • Top Ten Wearable Medical Device Solution Provider, according to MD Tech Review

2020

  • Top Ten Wearable Medical Device Solution Provider, according to MD Tech Review
  • Omnipod DASH® System named the 2020 Product of the Year in the Health Systems Category by 40,000 U.S. Consumers

The Human Side of Innovation - About the Team

What Does it Mean to Work on The Innovation Team at Insulet?

We’re passionate about pioneering new ways of thinking – whether that results in a product, a system, a process, or a pivot from prior ways of thinking to new insights.

What Makes Our Innovation Team Stand Out?

  • An implicit freedom to challenge the status quo
  • Technical skills, combined with critical thinking and creativity
  • Collaboration combined with deep focus
  • Diversity of thought and background

References:
1. https://www.healthline.com/diabetesmine/artificial-intelligence-daily-life-with-diabetes and https://www.youtube.com/watch?v=ST45EcJ82a0
2. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
3. 14 injections/day based on people with T1D on MDI taking ≥ 3 boluses and 1-2 basal injections/day multiplied by 72 hours. Chiang et al. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care. 2014:37:2034-2054.
4. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 controller is not waterproof
5. Dexcom G6® CGM System is sold separately
6.For a list of compatible smartphone devices visit omnipod.com/compatibility

Regional Disclaimer

Are you a resident of the United States?

Yes No

The content of the webpage that you are about to access is exclusively reserved for residents of the United States.

If you are a resident of the United States, please click 'Yes' to continue. If not, please click 'No' to exit and do not access the webpages. If you selected this country/language in error, you can go back to the previous page and select your country/language.

Thank you.